ACTRN12614000744651已完成未知
Physiological and Biochemical Responses to Fluid Bolus Therapy with 4% versus 20% Human Albumin Solution in Critically Ill Adults
Prof Rinaldo Bellomo0 个研究点目标入组 200 人开始时间: 2014年7月14日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •All adult ICU admissions who received either 4% or 20% (but not both) human albumin solution as fluid bolus therapy at our institution between April 2012 and March 2013
排除标准
- •1. Patients received both 4% and 20% solution within 24 hours of baseline
- •2. Patients who had previously received any human albumin solution during their ICU stay
研究者
相似试验
已完成
不适用
Indications and physiological effects of fluid bolus therapy in emergency department patientsACTRN12615001150538Department of ICCU, Flinders Medical Centre500
招募中
不适用
Effects of body electrical stimulation after the stomach reduction surgeryMorbidly obese patients undergoing bariatric surgeryC18.654.726.500.700E02.065.062RBR-99qw5hniversidade Federal de São Carlos
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)EUCTR2018-000462-11-ESBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-BEBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab incombination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer(NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer(NSCLC)MedDRA version: 20.0Level: LLTClassification code 10007096Term: Cancer of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO250